The Weight Loss Drug That Feeds the Disorder

A recent examination highlights important concerns regarding the use of GLP-1 medications among patients with eating disorders. Specifically, those with restrictive eating histories may find that such treatments exacerbate their conditions instead of improving them.

Concerns over Unscreened Eating Disorders

Research indicates that up to 26 percent of individuals pursuing treatment for obesity may have an undiagnosed eating disorder, yet these patients often go unscreened. This oversight carries significant risks, particularly for those with histories of restrictive eating, as appetite suppression can reinforce existing problematic behaviors rather than alleviate them.

Impact of GLP-1 Medications

GLP-1 medications, such as semaglutide, are designed to affect brain mechanisms related to hunger and reward. For some patients, particularly those with binge eating disorder, these drugs can provide a welcome relief from compulsive behaviors. However, individuals with backgrounds in restrictive eating may experience a detrimental effect. The neurological shifts induced by GLP-1 treatments can amplify pre-existing tendencies for restriction, as demonstrated in cases where patients began engaging in more harmful behaviors.

Clinical Observations and Recommendations

A 2026 article in the New England Journal of Medicine by physician Amanda Banks raised critical issues regarding the increase in GLP-1 prescriptions, particularly among individuals who do not meet criteria for obesity. Banks noted that prescriptions for non-diabetic patients surged from 4.5 percent in 2018 to 17 percent in 2023. This growth raises alarms about the lack of proper screening and follow-up practices for individuals with a history of eating disorders. Recommendations for more rigorous safety protocols have been proposed to ensure vulnerable populations are protected.

Screening Protocol Gaps

The current healthcare infrastructure does not adequately address the intersection between obesity treatment and eating disorders. Many telehealth intake forms focus solely on metabolic suitability, neglecting psychological aspects. Given that individuals with restrictive eating disorders frequently do not meet the clinical criteria for active eating disorders, many may pursue GLP-1 medications without adequate evaluation of their relationship with food. As a result, these patients might find themselves at increased risk for reactivated eating disorder behaviors.

THE CNP TAKEAWAY

Those with a history of restrictive eating behaviors should approach GLP-1 medications with caution. It is critical to conduct thorough screenings and consider psychological histories before initiating such treatments.

Images courtesy of Shutterstock.